Key Points
- Director Joseph Michael Taylor sold 10,200 CeriBell shares at an average price of $27.22, totaling $277,644. After the sale, he held 38,278 shares, a 21.04% reduction in his position.
- CeriBell’s latest quarter showed a loss of $0.55 per share, missing the $0.51 loss analysts expected; revenue of $29.34 million slightly exceeded estimates.
- Analysts’ average rating was “Moderate Buy”, with a consensus price target of $31.25. Shares opened at $27.48, near their reported 52-week high of $28.89.
CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) Director Joseph Taylor sold 10,200 shares of the stock in a transaction on Monday, November 9th. The stock was sold at an average price of $27.22, for a total transaction of $277,644.00. Following the completion of the sale, the director owned 38,278 shares in the company, valued at $1,041,927.16. The trade was a 21.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Joseph Michael Taylor also recently made the following trade(s):
- On Thursday, August 13th, Joseph Taylor sold 13,095 shares of CeriBell stock. The shares were sold at an average price of $23.40, for a total transaction of $306,423.00.
CeriBell Trading Down 0.4%
NASDAQ CBLL opened at $27.48 on Wednesday. CeriBell, Inc. has a 1 year low of $11.75 and a 1 year high of $28.89. The company has a debt-to-equity ratio of 0.17, a current ratio of 8.18 and a quick ratio of 7.79. The company has a market capitalization of $1.07 billion, a PE ratio of -14.16 and a beta of 0.86. The company has a fifty day moving average of $25.40 and a 200 day moving average of $20.97.
CeriBell (NASDAQ:CBLL - Get Free Report) last announced its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.04). The company had revenue of $29.34 million for the quarter, compared to analyst estimates of $29.18 million. CeriBell had a negative return on equity of 52.59% and a negative net margin of 67.96%. Research analysts forecast that CeriBell, Inc. will post -2.05 earnings per share for the current year.
Analyst Ratings Changes
Several analysts recently commented on CBLL shares. Weiss Ratings raised CeriBell from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, October 16th. Raymond James Financial reiterated a "strong-buy" rating and set a $29.00 price target on shares of CeriBell in a research report on Thursday, September 3rd. Barclays raised CeriBell to a "neutral" rating in a report on Tuesday, August 18th. TD Cowen upped their price objective on CeriBell from $29.00 to $33.00 and gave the stock a "buy" rating in a research report on Friday, October 2nd. Finally, BTIG Research reaffirmed a "buy" rating on shares of CeriBell in a research note on Wednesday, November 4th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, CeriBell has an average rating of "Moderate Buy" and a consensus target price of $31.25.
Get Our Latest Report on CeriBell
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Lisanti Capital Growth LLC purchased a new stake in shares of CeriBell during the 3rd quarter worth about $4,466,000. Squarepoint Ops LLC acquired a new stake in shares of CeriBell during the 2nd quarter valued at about $638,000. Wellington Management Group LLP grew its position in shares of CeriBell by 5.5% during the 2nd quarter. Wellington Management Group LLP now owns 87,698 shares of the company's stock valued at $1,706,000 after acquiring an additional 4,572 shares during the period. Formula Growth Ltd. purchased a new position in shares of CeriBell in the 2nd quarter valued at about $603,000. Finally, Bank of America Corp DE purchased a new position in shares of CeriBell in the 2nd quarter valued at about $4,619,000.
CeriBell Company Profile
(
Get Free Report)
Ceribell, Inc. develops neurodiagnostic technology for detecting and monitoring seizures. Its products are designed to make electroencephalography (EEG) more accessible in emergency departments and intensive care units, where timely assessment can be important and conventional EEG services may not be readily available. The company's Ceribell point-of-care EEG system combines a headband with electrodes, a portable recorder and software for viewing and analyzing EEG data. Its Clarity algorithm is designed to help clinicians identify patterns associated with seizure activity, while the system supports remote review by specialists.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
